+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 56 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations
P

Actively Recruiting

Researchers are conducting a prospective, multicenter observational study to create a registry for patients diagnosed with unresectable locally advanced or metastatic breast cancer, either after recurrence or as a first diagnosis since January 2016. This study aims to understand the distribution of different breast cancer subtypes and patient characteristics over an 8-year period. No specific treatment is assigned by the study, and clinical decisions are made independently by the treating physicians. Participants are grouped based on breast cancer subtypes characterized by receptors such as Estrogen receptor ER, Progesterone receptor PgR, HER2, and Ki-67 expression levels. The study does not intervene in treatment instead, it observes patients receiving standard care as decided by their doctors. Patients may include males and females, and there is no age upper limit. Data collection includes patient and tumor characteristics, biomarker presence in tumor and blood samples, and the impact of surgery timing on patients initially diagnosed with metastatic disease. During the study, participants medical records and disease management data are accessed for analysis. Researchers collect information over 8 years, including subtype distribution, heredofamilial risk, gender differences in disease progression, and biomarker frequency. Patients can withdraw consent at any time, and the treating clinician is encouraged to follow patients until death or study completion. The studys primary outcome is the number of patients with various breast cancer subtypes, with several secondary outcomes related to disease characteristics and treatment timing.

Age: 18Years +All Genders
40 locations
E

Actively Recruiting

Researchers are evaluating two imaging strategies to improve the treatment of patients with significant calcified coronary artery disease undergoing percutaneous coronary intervention PCI. The study compares a non-invasive coronary CT angiography CCTA-guided calcium modification approach with the current standard intravascular ultrasound IVUS-guided PCI to see if CCTA can enhance procedural efficiency and outcomes while maintaining similar safety. This prospective, multicenter, randomized controlled trial involves 700 patients with flow-limiting stenosis and moderate-to-severe calcification. Participants are randomly assigned to one of two groups one uses CCTA-guided calcium modification, which applies advanced CT imaging to plan and select plaque modification techniques before PCI the other uses IVUS-guided calcium modification following established intravascular ultrasound criteria for plaque preparation and stent optimization. Both groups receive post-procedural IVUS to confirm correct stent implantation. The study measures superiority in final minimal stent area and non-inferiority in 12-month target vessel failure. During the study, participants undergo pre-procedural imaging with either CT or IVUS to assess lesion characteristics. Researchers will evaluate procedure time, radiation exposure, contrast volume, stent area measurements, number of calcium fractures, and clinical safety outcomes including myocardial infarction and stent thrombosis. Patient-reported angina symptoms will also be tracked. The trial continues with follow-up assessments for 12 months to monitor clinical outcomes and safety, with the total participation lasting up to one year post-procedure.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
15 locations
P

Actively Recruiting

This trial is investigating whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome CRS in people with relapsed or refractory multiple myeloma. CRS is a sudden inflammatory reaction that can cause flu-like symptoms such as fever and tiredness during treatment. The study is a Phase 2, randomized, double-blind, placebo-controlled trial focused on prevention of CRS. Participants will be randomly assigned to receive either tocilizumab plus ramantamig or placebo plus ramantamig. Ramantamig is given as a subcutaneous injection for a finite duration or until the disease progresses or side effects become intolerable. Tocilizumab or placebo is administered as an intravenous injection before ramantamig treatment starts. Two groups are compared one receiving tocilizumab with ramantamig and the other receiving placebo with ramantamig. During the study, participants will be monitored for CRS symptoms and treatment responses up to 38 months. Researchers will assess the percentage of participants alive and free from significant CRS within 28 days after the first dose of ramantamig. Other measures include response rates, duration of response, progression-free survival, and adverse events. Laboratory tests, clinical exams, and safety monitoring are conducted regularly to evaluate the effects and side effects of the treatments.

Age: 18Years +All GendersPhase 2
60 locations
G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
P

Actively Recruiting

Researchers are evaluating a new treatment called ramantamig-D for people newly diagnosed with multiple myeloma, a type of blood cancer affecting plasma cells. This study compares ramantamig-D with standard treatments that include combinations of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants who are not planned to undergo stem cell transplant as their first therapy. Participants will be randomly assigned to receive either ramantamig-D by subcutaneous injection or one of two standard treatment regimens chosen by their doctor DVRd daratumumab, bortezomib, lenalidomide, and dexamethasone or DRd daratumumab, lenalidomide, and dexamethasone. The study will measure how long participants live without their disease worsening and the percentage achieving a complete response with no detectable cancer cells up to 12 months. During the trial, participants will be monitored for progression-free survival for about 62 months and other outcomes like overall survival and quality of life for up to 100 months. Assessments will include disease response rates, adverse events, and patient-reported outcomes. Participants will have scheduled visits and evaluations to carefully track treatment effects and safety throughout the study.

Age: 18Years +All GendersPhase 3
103 locations
S

Actively Recruiting

Multiple myeloma is a cancer that affects plasma cells in the blood, often found in bones and bone marrow. It can cause bone pain, fractures, infections, weak bones, and kidney failure. This research aims to study the side effects, disease activity changes, and how the body processes the drug Etentamig in adults with newly diagnosed multiple myeloma who are not eligible for transplant. The study is divided into two phases. In phase 2, participants receive one of three intravenous doses of Etentamig combined with subcutaneous injections of daratumumab, or one of two subcutaneous doses of Etentamig combined with daratumumab. In phase 3, participants receive the recommended phase 3 dose of Etentamig intravenously with daratumumab, or a combination of daratumumab, lenalidomide capsules, and dexamethasone tablets or intravenous injections. The study lasts about 16 years. Participants will attend regular visits at hospitals or clinics for medical exams, blood tests, side effect monitoring, and questionnaires. Researchers will assess adverse events, minimal residual disease, progression-free survival, and quality of life measures over time. The long study duration allows tracking of treatment effects, safety, and disease status across phases 2 and 3.

Age: 18Years +All GendersPhase 2Phase 3
49 locations
C

Actively Recruiting

Researchers are studying post-menopausal women who have been treated for hormone receptor-positive early breast cancer. The study compares the amount of the drug letrozole in the bloodstream after multiple doses of a quarterly injectable form called Letrozole SIE to that after multiple doses of the standard daily oral tablet, Femara4. The goal is to evaluate how the two forms of letrozole compare in steady-state bioavailability, and to understand the elimination phase of Letrozole SIE after repeated doses. The study has four parts a Screening period, Treatment Period 1 TP1, Treatment Period 2 TP2, and an Extension Period. After screening, participants are randomly assigned to receive either US-sourced or EU-sourced oral Femara4 daily for 14 days in TP1 to reach steady-state drug levels. Then, in TP2, all participants receive quarterly injections of Letrozole SIE to achieve steady-state. A subset of about 60 participants will continue into the Extension Period to further assess drug elimination after multiple doses. Participants will undergo breast imaging before baseline and regular assessments including drug concentration measurements, bone mineral density scans, and monitoring for adverse events and injection site reactions. The primary measure is the area under the concentration-time curve at steady state. Safety and other pharmacokinetic parameters will be tracked from consent through the follow-up visits, which may last up to 421 days for some participants. The total study duration includes screening, treatment, and possible extension periods.

Age: 18Years - 80YearsFEMALEPhase 1
21 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two drug combinations for adults with relapsed or refractory multiple myeloma, a type of blood cancer. This study compares mezigdomide combined with bortezomib and dexamethasone MeziVd against pomalidomide combined with bortezomib and dexamethasone PVd in participants who have received one to three previous therapies including lenalidomide. The goal is to find out which treatment better controls the disease and how well patients tolerate these combinations. Participants are randomly assigned to receive either MeziVd or PVd treatment. Each drug is given at specified doses on certain days, and the study is open-label, meaning both participants and researchers know the assigned treatment. The study lasts up to approximately five years, allowing long-term monitoring and assessment of disease progression and survival. Additional measurements include drug levels in the blood, response rates, quality of life questionnaires, and safety evaluations. During the study, participants will have regular assessments to monitor their disease status, treatment response, and side effects. Progression-free survival, the time until disease worsens or death, is the main outcome measured. Other outcomes include overall survival, response quality, time to next treatment, and quality of life changes. Safety is closely monitored through adverse event reporting. The study provides important data to understand how these drug combinations work in relapsed or refractory multiple myeloma over an extended period.

Age: 18Years +All GendersPhase 3
266 locations

1-10 of 56

1